Rare though not mutually exclusive: A report of three cases of concomitant kras and braf mutation and a review of the literatuer

Journal of Cancer

Volumn 4, Issue 4, 2013, Pages 320-322

  Sahin, Ibrahim Halil ^a   Kazmi, Syed M A ^a   Yorio, Jeffrey T ^a   Bhadkamkar, Nishin A ^a   Kee, Bryan K ^a   Garrett, Christo pher R ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

BRAF; Concomitant KRAS

Indexed keywords

B RAF KINASE; K RAS PROTEIN;

ADULT; AGED; ARTICLE; CASE REPORT; CODON; COLON TUMOR; COLORECTAL CANCER; COLORECTAL LIVER METASTASIS; DESCENDING COLON; EXON; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; LUNG METASTASIS; MALE; RECTUM CANCER; RETROSPECTIVE STUDY; TRANSVERSE COLON;

EID: 84883001378     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.3619     Document Type: Article

References (13)

1. Lin JS, Webber EM, Senger CA, Holmes RS, Whitlock EP. Systematic review of pharmacogenetic testing for predicting clinical benefit to anti-EGFR therapy in metastatic colorectal cancer. American journal of cancer research. 2011; 1: 650-62.
2. Lang AH, Drexel H, Geller-Rhomberg S, Stark N, Winder T, Geiger K, et al. Optimized allele-specific real-time PCR assays for the detection of common mutations in KRAS and BRAF. The Journal of molecular diagnostics : JMD. 2011; 13: 23-8. doi:10.1016/j.jmoldx.2010.11.007.
3. Seth R, Crook S, Ibrahem S, Fadhil W, Jackson D, Ilyas M. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer. Gut. 2009; 58: 1234-41. doi:10.1136/gut.2008.159137.
4. Oliveira C, Velho S, Moutinho C, Ferreira A, Preto A, Domingo E, et al. KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression. Oncogene. 2007; 26: 158-63. doi:10.1038/sj.onc.1209758.
5. Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011; 29: 2011-9. doi:10.1200/JCO.2010.33.5091.
6. Lamy A, Blanchard F, Le Pessot F, Sesboue R, Di Fiore F, Bossut J, et al. Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2011; 24: 1090-100. doi:10.1038/modpathol.2011.60.
7. Price TJ, Hardingham JE, Lee CK, Weickhardt A, Townsend AR, Wrin JW, et al. Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011; 29: 2675-82. doi:10.1200/JCO.2010.34.5520.
8. Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet. 2011; 377: 2103-14. doi:10.1016/S0140-6736(11)60613-2.
9. Li HT, Lu YY, An YX, Wang X, Zhao QC. KRAS, BRAF and PIK3CA mutations in human colorectal cancer: relationship with metastatic colorectal cancer. Oncology reports. 2011; 25: 1691-7. doi:10.3892/or.2011.1217.
10. Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2011; 22: 1535-46. doi:10.1093/annonc/mdq632.
11. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010; 11: 753-62. doi:10.1016/S1470-2045(10)70130-3.
12. Tejpar S, Popovici V, Dolarenzi M, Budinska E, Estrella H, Mao M, et al. Mutant KRAS and BRAF gene expression profiles in colorectal cancer: Results of the translational study on the PETACC 3-EORTC 40993-SAKK 60-00 trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010; 28:15s.
13. De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA : the journal of the American Medical Association. 2010; 304: 1812-20. doi:10.1001/jama.2010.1535.